Long-term remission of HIV-associated thrombocytopenia parallels ongoing suppression of viral replication

Western Journal of Medicine

Volumn 167, Issue 6, 1997, Pages 433-435

  Zell, Steven C ^a,b   Peterson, Kevin ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b Renown Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN;

ADULT; CASE REPORT; DRUG COMBINATION; DRUG EFFECT; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHYSIOLOGY; REMISSION; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIC PURPURA; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC; REMISSION INDUCTION; VIRUS REPLICATION;

EID: 0031305805     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Street A. Gibson J. HIV and haematological disease. Med J Aust 1996; 164:487-8
2. Glatt A, Anand A. Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Clin Infect Dis 1995; 21(2):415-423
3. Harbol A, Liesveld J, Simpson-Haidaris P, Abboud C. Mechanisms of cytopenia in human immunodeficiency virus infection. Blood Rev 1994; 8(4):241-251
4. Davis B, Zauli G. Effect of human immunodeficiency virus infection on haematopoiesis. Baillieres Clin Haematol 1995; 8(1):113-130
5. Landonio G, Nosari A, Spinelli F. HIV-related thrombocytopenia (Letter). N Eng J Med 1993; 328(24):1785
6. Zauli G, Catani L, Gibellini D, et al. Impaired survival of bone marrow epIIb/II at megakaryocytic cells as an additional pathogenic mechanism of HIV-1-related thrombocytopenia. Br J Haematol 1996; 92(3):711-717
7. Najean Y, Rain J. The mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. J Lab Clin Med 1994; 123(3):415-420
8. Bettaieb A, Oksenhendler E, Duedari N, Bierling P. Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Clin Exp Immunol 1996; 103(1):19-23
9. Gonzalez-Conejero R, Rivera J, Rosillo M, Cano A, Rodriguez T, Vicente V. Association of autoantibodies against platelet glycoproteins Ib/lX and IIb/IIIa and platelet-reactive anti-HIV antibodies in thrombocytopenic narcotic addicts. Br J Haematol 1996; 93(2):464-471
10. Luster M, Rosenthal G, Cao W, et al. Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection. Int J Immunopharmacol 1991; 13 suppl 1:99-107
11. Brogan K, Zell S. Hematologic toxicity of zidovudine in HIV-infected patients. Am Fam Phys 1990; 41(5):1521-1528
12. Rarick M, Espina B, Montgomery T, Easley A, Allen J, Levine A. The long-term use of zidovudine in patients with severe immune-mediated thrombocytopenia secondary to infection with HIV. AIDS 1993; 7(2):209-212
13. Aster R, Williams W. Thrombocytopenia in the HIV-infected patient. Hospital Practice 1994; 29(8):81-86
14. Boyar A, Beall G. HIV-seropositive thrombocytopenia. the action of zidovudine. AIDS 1991; 5(11):1351-1356
15. Jahnkee L, Applebaum S, Sherman L, Greenberger P, Green D. An evaluation of intravenous immunoglobin in the treatment of human immunodeficiency virus-associated thrombocytopenia. Transfusion 1994; 34(9):759-764
16. Northfelt D, Charlebois E, Mirda M, Child C, Kaplan L, Abrams D. Continuous low-dose interferon-alpha therapy for HIV-related ITP. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8(1):45-50
17. Ramratnam B, Parameswaran J, Elliot B, et al. Short course dexamethasone for thrombocytopenia in AIDS. Am J Med 1996; 100(1):117-118
18. Landonio G, Cinque P, Nosari A, et al. Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia. AIDS 1993; 7(2):209-212
19. Cinque P, Landonio G, Lazzarin A, et al. Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia: modes of response and correlation with markers of HIV replication. Eur J Haematol 1993; 50(1):17-21
20. Pottage J, Benson C, Spear J, Landay A, Kessler H. Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine. JAMA 1988; 260(20):3045-3048
21. Lange J. Triple combinations: present and future. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 suppl 1:S77-S82
22. Goebel F. Combination therapy from a clinician's perspective. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 suppl 1:S62-S68
23. Carpenter CC, Fischi MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996; 276(2):146-154
24. Harrigan R. Measuring viral load in the clinical setting. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 suppl 1:S34-S40
25. Merigan T. Individualization of therapy using viral markers. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 suppl 1:S41-S46
26. St Clair M, Pennington K, Rooney J, Barry D. Rapid screening of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 suppl 1:S24-S27
27. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA 1997; 277(24):1962-1969